scholarly journals Gene Expression Changes in a Model Neuron Cell Line Exposed to Autoantibodies from Patients with Traumatic Brain Injury and/or Type 2 Diabetes

Author(s):  
Mark B. Zimering ◽  
Vedad Delic ◽  
Bruce A. Citron

AbstractTraumatic brain injury and adult type 2 diabetes mellitus are each associated with the late occurrence of accelerated cognitive decline and Parkinson’s disease through unknown mechanisms. Previously, we reported increased circulating agonist autoantibodies targeting the 5-hydroxytryptamine 2A receptor in plasma from subsets of Parkinson’s disease, dementia, and diabetic patients suffering with microvascular complications. Here, we use a model neuron, mouse neuroblastoma (N2A) cell line, to test messenger RNA expression changes following brief exposure to traumatic brain injury and/or type 2 diabetes mellitus plasma harboring agonist 5-hydroxytryptamine 2A receptor autoantibodies. We now report involvement of the mitochondrial dysfunction pathway and Parkinson’s disease pathways in autoantibody-induced gene expression changes occurring in neuroblastoma cells. Functional gene categories upregulated significantly included cell death, cytoskeleton-microtubule function, actin polymerization or depolymerization, regulation of cell oxidative stress, mitochondrial function, immune function, protein metabolism, and vesicle function. Gene categories significantly downregulated included microtubule function, cell adhesion, neurotransmitter release, dopamine metabolism synaptic plasticity, maintenance of neuronal differentiation, mitochondrial function, and cell signaling. Taken together, these results suggest that agonist 5-hydroxytryptamine receptor autoantibodies (which increase in Parkinson’s disease and other forms of neurodegeneration) mediate a coordinating program of gene expression changes in a model neuron which predispose to neuro-apoptosis and are linked to human neurodegenerative diseases pathways.

2014 ◽  
Vol 13 (3) ◽  
pp. 418-428 ◽  
Author(s):  
Marcelo Lima ◽  
Adriano Targa ◽  
Ana Noseda ◽  
Lais Rodrigues ◽  
Ana Delattre ◽  
...  

Author(s):  
Almudena Sánchez-Gómez ◽  
Yesika Díaz ◽  
Talita Duarte-Salles ◽  
Yaroslau Compta ◽  
Maria José Martí

Aging ◽  
2020 ◽  
Vol 12 (15) ◽  
pp. 15682-15704 ◽  
Author(s):  
Ting Wang ◽  
Feilan Yuan ◽  
Zhenze Chen ◽  
Shuzhen Zhu ◽  
Zihan Chang ◽  
...  

2020 ◽  
pp. 1-15 ◽  
Author(s):  
Julia L.Y. Cheong ◽  
Eduardo de Pablo-Fernandez ◽  
Thomas Foltynie ◽  
Alastair J. Noyce

2020 ◽  
Author(s):  
Catherine S. Storm ◽  
Demis A. Kia ◽  
Mona Almramhi ◽  
Dilan Athauda ◽  
Stephen Burgess ◽  
...  

AbstractBackgroundExenatide is a glucagon-like peptide 1 receptor (GLP1R) agonist used in type 2 diabetes mellitus that has shown promise for Parkinson’s disease in a phase II clinical trial. Drugs with genetic evidence are more likely to be successful in clinical trials. In this study we investigated whether the genetic technique Mendelian randomization (MR) can “rediscover” the effects of exenatide on diabetes and weight, and predict its efficacy for Parkinson’s disease.MethodsWe used genetic variants associated with increased expression of GLP1R in blood to proxy exenatide, as well as variants associated with expression of DPP4, TLR4 and 15 genes thought to act downstream of GLP1R or mimicking alternative actions of GLP-1 in blood and brain tissue. Using an MR approach, we predict the effect of exenatide on type 2 diabetes risk, body mass index (BMI), Parkinson’s disease risk and several Parkinson’s disease progression markers.ResultsWe found that genetically-raised GLP1R expression in blood was associated with lower BMI and possibly type 2 diabetes mellitus risk, but not Parkinson’s disease risk, age at onset or progression. Reduced DPP4 expression in brain tissue was significantly associated with increased Parkinson’s disease risk.ConclusionsWe demonstrate the usefulness of MR using expression data in predicting the efficacy of a drug and exploring its mechanism of action. Our data suggest that GLP-1 mimetics like exenatide, if ultimately proven to be effective in Parkinson’s disease, will be through a mechanism that is independent of GLP1R in blood.


Sign in / Sign up

Export Citation Format

Share Document